Cover Image

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Abstract Antibody‐mediated removal of aggregated β‐amyloid (Aβ) is the current, most clinically advanced potential disease‐modifying treatment approach for Alzheimer's disease. We describe a quantitative systems pharmacology (QSP) approach of the dynamics of Aβ monomers, oligomers, protofibrils...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hugo Geerts (Author), Mike Walker (Author), Rachel Rose (Author), Silke Bergeler (Author), Piet H. van derGraaf (Author), Edgar Schuck (Author), Akihiko Koyama (Author), Sanae Yasuda (Author), Ziad Hussein (Author), Larisa Reyderman (Author), Chad Swanson (Author), Antonio Cabal (Author)
Format:	Book
Published:	Wiley, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
by: Seiichi Hayato, et al.
Published: (2022)

Salvaging CNS Clinical Trials Halted Due to COVID‐19
by: Hugo Geerts, et al.
Published: (2020)

Pharmacometrics and/or Systems Pharmacology
by: Piet H. van derGraaf
Published: (2019)

A yeast model for amyloid-β aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity
by: Fabien D'Angelo, et al.
Published: (2013)

Three to Tango: Inhibitory Effect of Quercetin and Apigenin on Acetylcholinesterase, Amyloid-β Aggregation and Acetylcholinesterase-Amyloid Interaction
by: Irene Álvarez-Berbel, et al.
Published: (2022)

Prediction of fibril formation by early-stage amyloid peptide aggregation
by: Jiaojiao Hu, et al.
Published: (2020)

Differential effects of NSAIDs on amyloid β1-42 peptide aggregation
by: Atheer Al-Zurfi, et al.
Published: (2019)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
by: Hugo Geerts, et al.
Published: (2020)

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development
by: Sharmin Reza Chowdhury, et al.
Published: (2019)

Evaluation of Amyloid Polypeptide Aggregation Inhibition and Disaggregation Activity of A-Type Procyanidins
by: Taisei Tanaka, et al.
Published: (2021)

Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties
by: Maria Kozurkova, et al.
Published: (2011)

QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation
by: Richard J. Matthews, et al.
Published: (2023)

Inhibition of Acetylcholinesterase and Amyloid-β Aggregation by Piceatannol and Analogs: Assessing In Vitro and In Vivo Impact on a Murine Model of Scopolamine-Induced Memory Impairment
by: Yi-Yan Sie, et al.
Published: (2023)

Role of the Metal Center in the Modulation of the Aggregation Process of Amyloid Model Systems by Square Planar Complexes Bearing 2-(2'-pyridyl)benzimidazole Ligands
by: Daniele Florio, et al.
Published: (2019)

Dual-target ligand discovery for Alzheimer's disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation
by: Marwa El-Hussieny, et al.
Published: (2023)

Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer's disease
by: Hongtao Du, et al.
Published: (2023)

Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation
by: Magdalena Markowicz-Piasecka, et al.
Published: (2018)

Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and β-amyloid Aggregation
by: Liang-Chieh Chen, et al.
Published: (2018)

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease
by: Serena Vittorio, et al.
Published: (2020)

Exploring the Early Stages of the Amyloid Aβ(1-42) Peptide Aggregation Process: An NMR Study
by: Angelo Santoro, et al.
Published: (2021)

A phlorotannin isolated from Ecklonia radiata, Dibenzodioxin-fucodiphloroethol, inhibits neurotoxicity and aggregation of β-amyloid
by: Srijan Shrestha, et al.
Published: (2021)

Learn-confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform
by: Linnea C. Franssen, et al.
Published: (2023)

Application of quantitative systems pharmacology to guide the optimal dosing of COVID‐19 vaccines
by: Mario Giorgi, et al.
Published: (2021)

INFLUENCE OF CERTAIN D-METALS ON FORMATION OF ADVANCED GLYCATION END PRODUCTS, AGGREGATION AND AMYLOID TRANSFORMATION OF ALBUMIN IN GLYCATION REACTION
by: R. A. Litvinov, et al.
Published: (2021)

A Systematic Screening of Traditional Chinese Medicine Identifies Two Novel Inhibitors Against the Cytotoxic Aggregation of Amyloid Beta
by: Liang Ma, et al.
Published: (2021)

Acidic Oligosaccharide Sugar Chain, a Marine-Derived Acidic Oligosaccharide, Inhibits the Cytotoxicity and Aggregation of Amyloid Beta Protein
by: Jinfeng Hu, et al.
Published: (2004)

Model‐informed target identification and validation through combining quantitative systems pharmacology with network‐based analysis
by: Vijayalakshmi Chelliah, et al.
Published: (2022)

Phenolic composition, antioxidant activity, anticholinesterase potential and modulatory effects of aqueous extracts of some seaweeds on β-amyloid aggregation and disaggregation
by: Tosin A. Olasehinde, et al.
Published: (2019)

A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability
by: Douglas Chung, et al.
Published: (2023)

Therapeutic effect of Melissa officinalis in an amyloid-β rat model of Alzheimer's disease
by: Siamak Beheshti, et al.
Published: (2018)

Induced neuronal activity does not attenuate amyloid beta‐induced synaptic loss in vitro
by: Rena Kono, et al.
Published: (2019)

Amyloid-β
Published: (2023)

Amyloid Diseases
Published: (2019)

Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer's disease
by: Galina F. Makhaeva, et al.
Published: (2023)

Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid
by: Lin Lin, et al.
Published: (2022)

Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer's Disease
by: Heeyoung Kang, et al.
Published: (2021)

Moving the needle for oncology dose optimization: A call for action
by: Karthik Venkatakrishnan, et al.
Published: (2024)

Moving the needle for oncology dose optimization: A call for action
by: Karthik Venkatakrishnan, et al.
Published: (2024)

β-Asarone Inhibits Amyloid-β by Promoting Autophagy in a Cell Model of Alzheimer's Disease
by: Nanbu Wang, et al.
Published: (2020)

Oligomeric amyloid-β targeted contrast agent for MRI evaluation of Alzheimer's disease mouse models
by: Jang Woo Park, et al.
Published: (2024)